We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for asciminib hydrochloride (Novartis Pharmaceuticals Australia Pty Ltd)
Active ingredients
asciminib hydrochloride
Date of review outcome
Lapse date
Type
Priority review
Indication
For the treatment of patients 18 years of age and above with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP)
Therapeutic area
Haematology